Roche’s COVID-19 test detects, differentiates BA.2.75

written by CAP TODAY
August 22, 2022

Aug. 22, 2022—Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the BA.2.75 subvariant.

Bio-Rad launches two negative run controls

written by CAP TODAY
August 22, 2022

August 2022—Bio-Rad Laboratories launched two new Exact Diagnostics products. The Exact Diagnostics Synthetic Negative Run Control is screened negative for nine targets, *Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis,* enterovirus coxsackievirus A9, HSV-1 and HSV-2, and varicella zoster virus. The Exact Diagnostics HAI Negative Run Control is screened negative for *Clostridium difficile*, methicillin-resistant *Staphylococcus aureus*, and methicillin-susceptible *Staphylococcus aureus*.

BD unveils spectral cell sorter with high-speed imaging technology

written by CAP TODAY
August 22, 2022

August 2022—BD has unveiled its BD FACSDiscover S8 Cell Sorter with BD CellView Image Technology, which captures images of individual cells flowing through the system and sorts them based on detailed microscopic image analysis of each one at high sort speeds.

Roche launches BenchMark Ultra Plus, Ventana DP 600

written by CAP TODAY
August 22, 2022

August 2022—Roche has launched its BenchMark Ultra Plus tissue staining platform. The system was built on the technology of the BenchMark Ultra and uses improved Ventana system software, which aims to enhance quality control and inventory management.

Thermo Scientific, Inpeco to develop LC-MS/MS, TLA connectivity

written by CAP TODAY
August 22, 2022

August 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco S.A. FlexLab total laboratory automation system.

CorePath, Cizzle Biotech to develop early-stage lung cancer test

written by CAP TODAY
August 22, 2022

August 2022—CorePath Laboratories announced a partnership with U.K.-based diagnostics developer Cizzle Biotech to develop and offer a proprietary early-stage lung cancer test throughout the United States. Cizzle Biotech's proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, Cizzle Biotech says, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

Reference materials for urine chemistry, bilirubin assays

written by CAP TODAY
August 22, 2022

August 2022—Verichem Laboratories now offers a range of liquid-stable and ready-to-use biosynthetic clinical reference materials for use with urine chemistry assays and designed for system calibration and calibration verification testing on a variety of clinical testing platforms, including from Abbott, Beckman Coulter, Roche, and Siemens Healthineers.

Bruker launches NMR-based long COVID test

written by CAP TODAY
August 22, 2022

August 2022—Bruker Corp. has launched PhenoRisk PACS RuO, a research use only nuclear magnetic resonance test for molecular phenomics research on blood samples of patients with post-acute COVID syndrome (PACS), or long COVID. The test uses a multiplexed combination of biomarkers and is for research on early-stage risk factors on longitudinal recovery monitoring and on potential secondary organ damage in cardiovascular disease, type 2 diabetes, kidney dysfunction, and inflammation. It runs on the Avance IVDr NMR spectroscopy system, which produces results in 20 minutes.

CSF false-bottom tube

written by CAP TODAY
August 22, 2022

August 2022—Sarstedt announced the availability of a false-bottom tube for cerebrospinal fluid with an elevated conical base. The tube was developed and validated for Roche, specifically for use with Roche's new generation of Elecsys immunoassays designed to detect Alzheimer's disease biomarkers on Cobas e analyzers. The tubes are manufactured from medical-grade polypropylene and have HDPE screw caps that are leak resistant at 95 kilopascals.

CE-IVD-marked TaqPath respiratory viral panel

written by CAP TODAY
August 22, 2022

August 2022—Thermo Fisher Scientific has launched its Applied Biosystems TaqPath Respiratory Viral Select panel. The CE-IVD-marked molecular assay panel provides results in approximately three hours and tests for adenovirus, human metapneumovirus, rhinovirus/enterovirus, and parainfluenza virus using PCR technology. RNase P and positive controls are included to offer sample-to-result reliability. The solution is scalable, allowing laboratories to run from one to 94 samples simultaneously.